MedTrace Logo

Efficacy and Safety of MMFS in Early AD

NCT03531684 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-09-09

No results posted yet for this study

Summary

This study is designed to evaluate the safety and efficacy of MMFS for improving cognition and global function in patients with probable Early Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

MMFS-205-SR

Twice daily, oral, 500 mg tablets

DIETARY_SUPPLEMENT

Placebo

Twice daily, oral

Sponsors & Collaborators

  • Ohio State University

    collaborator OTHER

  • Neurocentria, Inc.

    lead INDUSTRY

Principal Investigators

  • Douglas W Scharre, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-20
Primary Completion
2020-04-22
Completion
2020-04-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03531684 on ClinicalTrials.gov